Dr. Parsa on the Administration of the G-200 Vaccine in GBM

Video

Andrew T. Parsa, MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for patients with recurrent glioblastoma multiforme.

Andrew T. Parsa, MD, PhD, Associate Professor in Residence of Neurological Surgery, University of California, San Francisco, describes the administration of the prophage G-200 for recurrent glioblastoma multiforme.

A patient does not have to go through leukapheresis, nor receive additional cytokines such as GM-CSF, a common approach for many types of vaccines for brain tumor patients. As a part of standard of care, a patient undergoes surgical resection. That resected tissue is used to make the vaccine. In a majority of cases, patients who have a recurrent glioblastoma can have the vaccine made from surgical resection without an issue.

A physician will administer as many doses as a patient can tolerate with regard to the amount of vaccine, up to six, Parsa says.

Related Videos
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD